Coverage under Québec’s public drug plan provides access to the first therapy approved by Health Canada for this rare genetic disease.
Illuminating life at the cellular level
Coverage under Québec’s public drug plan provides access to the first therapy approved by Health Canada for this rare genetic disease.
In La Presse, Paul Lévesque, President and CEO of Celystra Pharma, makes the case for revitalizing Quebec’s pharmaceutical industry in the face of the Trump administration’s “most favoured nation” rule, which threatens Canadians’ access to new medicines. He calls on the government to bring health and economic development together to make Quebec a global leader in life sciences.
Paul Lévesque, President, CEO and Co-Founder of CELYSTRA Pharma, spoke at the 25th Annual Market Access Summit. He discussed launch strategy in Canada amid long approval timelines and global uncertainty.